top of page
The Professional Network for Healthcare Experts
Biogen Advances Tau-Targeting Alzheimer’s Drug Diranersen Despite Phase II Dose Uncertainty
Detailed CELIA trial results show Biogen and Ionis’ diranersen slowed cognitive decline in early Alzheimer’s disease, but questions remain over why the lowest dose delivered the strongest clinical benefit.
nuaxia
Jul 154 min read
Biogen Expands Immunology Pipeline with Up to $1B Acquisition of RayThera
Biogen has agreed to acquire RayThera in a deal worth up to $1 billion, strengthening its position in immunology and adding a portfolio of small-molecule anti-inflammatory candidates to its development pipeline.
nuaxia
Jun 222 min read
bottom of page